Association of rs1801582 and rs1801334 PARK2 Polymorphisms with risk of Parkinson's disease: A case-control study in South India and Meta-Analysis

Meta Gene

Volumn 10, Issue , 2016, Pages 32-38

  Ramakrishnan, V ^a   Alphonsa, T Alu ^a   Husain, RS Akram ^a   Ahmed, Shiek SSJ ^a   Subramaniyan, K ^a   Kumar, Suresh ^b  

^a CHETTINAD HOSPITAL AND RESEARCH INSTITUTE   (India)

^b BHARATH UNIVERSITY   (India)

Author keywords

Genotyping; Meta analysis; PARK2 gene; Parkinson's disease; SNP

Indexed keywords

ADULT; AGAR GEL ELECTROPHORESIS; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PARK2 GENE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 84991225184     PISSN: None     EISSN: 22145400     Source Type: Journal    
DOI: 10.1016/j.mgene.2016.09.007     Document Type: Article

References (47)

1. Aarsland, D., Bronnick, K., Ehrt, U., De Deyn, P.P., Tekin, S., Emre, M., et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J. Neurol. Neurosurg. Psychiatry 78 (2007), 36–42.
2. Bekris, L.M., Mata, I.F., Zabetian, C.P., The Genetics of Parkinson Disease. J. Geriatr. Psychiatry Neurol. 23 (2011), 228–242.
3. Bertram, L., Tanzi, R.E., The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 115 (2005), 1449–1457.
4. Biswas, A., Maulik, M., Das, S., Ray, K., Ray, J., Parkin polymorphisms: risk for Parkinson's disease in Indian population. Clin. Genet. 72 (2007), 484–486.
5. Brinza, D., Zelikovsky, A., Case (Control)-Free Multi-SNP Combinations in Case-Control Studies. 2006.
6. Brooks, J., Ding, J., Simon-Sanchez, J., Paisan-Ruiz, C., Singleton, A.B., Scholz, S.W., Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control. J. Med. Genet. 46 (2009), 375–381.
7. Cicchetti, F., Drouin-Ouellet, J., Gross, R.E., Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?. Trends Pharmacol. Sci. 30 (2009), 475–483.
8. De Carvalho, A.P., Lessa, P.S., Junior, C.G., Barsottini, O., Felício, A.C., Borges, V., et al. Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients. Mov. Disord. 23 (2008), 1228–1233.
9. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986), 177–188.
10. Eerola, J., Launes, J., Hellström, O., Tienari, P.J., Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland. Neurosci. Lett. 330 (2002), 296–298.
11. Egger, M., Smith, G.D., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
12. Emre, M., Aarsland, D., Brown, R., Burn, D.J., Duyckaerts, C., Mizuno, Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 22 (2007), 1689–1707.
13. Fleiss, J., Review papers: The statistical basis of meta-analysis. Stat. Methods Med. Res. 2 (1993), 121–145.
14. Funkiewiez, A., Ardouin, C., Caputo, E., Krack, P., Fraix, V., Klinger, H., et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 75 (2004), 834–839.
15. García, S., Lopez-Hernández, L.B., Suarez-Cuenca, J.A., Solano-Rojas, M., Gallegos-Arreola, M.P., Gama-Moreno, O., et al. Low prevalence of most frequent pathogenic variants of six PARK genes in sporadic Parkinson's disease. Folia Neuropathol. 52 (2014), 22–29.
16. Gaweda-Walerych, K., Safranow, K., Jasinska-Myga, B., Bialecka, M., Klodowska-Duda, G., Rudzinska, M., et al. PARK2 variability in Polish Parkinson's disease patients-interaction with mitochondrial haplogroups. Parkinsonism Relat. Disord. 18 (2012), 520–524.
17. Han, W., Liu, Y., Mi, Y., Zhao, J., Liu, D., Tian, Q., Alpha-synuclein (SNCA) polymorphisms and susceptibility to Parkinson's disease: A meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 168 (2015), 123–134.
18. Hernan, M.A., Takkouche, B., Caamaño-Isorna, F., Gestal-Otero, J.J., A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52 (2002), 276–284.
19. Hu, C.-J., Sung, S.-M., Liu, H.-C., Lee, C.-C., Tsai, C.-H., Chang, J.-G., Polymorphisms of the parkin gene in sporadic Parkinson's disease among Chinese in Taiwan. Eur. Neurol. 44 (2000), 90–93.
20. Inamdar, N.N., Arulmozhi, D.K., Tandon, A., Bodhankar, S.L., Parkinson's disease: Genetics and Beyond. Curr. Neuropharmacol. 5 (2007), 99–113.
21. Kay, D.M., Moran, D., Moses, L., Poorkaj, P., Zabetian, C.P., Nutt, J., et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann. Neurol. 61 (2007), 47–54.
22. Klein, C., Westenberger, A., Genetics of Parkinson's Disease. Cold Spring Harb. Perspect. Med. 2 (2012), 15–21.
23. Koziorowski, D., Hoffman-Zacharska, D., Sławek, J., Szirkowiec, W., Janik, P., Bal, J., et al. Low frequency of the PARK2 gene mutations in Polish patients with the early-onset form of Parkinson disease. Parkinsonism Relat. Disord. 16 (2010), 136–138.
24. Lesage, S., Lohmann, E., Tison, F., Durif, F., Dürr, A., Brice, A., et al. Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J. Med. Genet. 45 (2008), 43–46.
25. Lincoln, S.J., Maraganore, D.M., Lesnick, T.G., Bounds, R., De Andrade, M., Bower, J.H., et al. Parkin variants in North American Parkinson's disease: cases and controls. Mov. Disord. 18 (2003), 1306–1311.
26. Liu, X., Cheng, R., Verbitsky, M., Kisselev, S., Browne, A., Mejia-Sanatana, H., et al. Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med. Genet. 3 (2011), 12–18.
27. Lucking, C.-B., Chesneau, V., Lohmann, E., Verpillat, P., Dulac, C., Bonnet, A.-M., et al. Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. Arch. Neurol. 60 (2003), 1253–1256.
28. Mata, I.F., Alvarez, V., Garcı́a-Moreira, V., Guisasola, L.M., Ribacoba, R., Salvador, C., et al. Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease. Neurosci. Lett. 329 (2002), 149–152.
29. Medrano, R.F.V., de Oliveira, C.A., Guidelines for the tetra-primer ARMS–PCR technique development. Mol. Biotechnol. 56 (2014), 599–608.
30. Mhyre, T.R., Boyd, J.T., Hamill, R.W., Maguire-Zeiss, K.A., Parkinson's Disease. Subcell. Biochem. 65 (2012), 389–455.
31. Miller, S., Dykes, D., Polesky, H., A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16 (1988), 1215–1218.
32. Mizuno, Y., Hattori, N., Mori, H., Suzuki, T., Tanaka, K., Parkin and Parkinson's disease. Curr. Opin. Neurol. 14 (2001), 477–482.
33. Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46 (2014), 989–993.
34. Okubadejo, N., Britton, A., Crews, C., Akinyemi, R., Hardy, J., Singleton, A., et al. Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. PLoS One, 3(10), 2008, e3421.
35. Oliveri, R.L., Zappia, M., Annesi, G., Bosco, D., Annesi, F., Spadafora, P., et al. The parkin gene is not involved in late-onset Parkinson's disease. Neurology 57 (2001), 359–362.
36. Ondo, W., Vuong, K.D., Khan, H., Atassi, F., Kwak, C., Jankovic, J., Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 57 (2001), 1392–1396.
37. Pezzoli, G., Cereda, E., Exposure to pesticides or solvents and risk of Parkinson disease. Neurology 80 (2013), 2035–2041.
38. Sanyal, J., Sarkar, B., Scenario of Parkinsons Disease in India. Guidel. Contrib. 57 (2012), 534–550.
39. Sanyal, J., Jana, A., Ghosh, E., Banerjee, T.K., Chakraborty, D.P., Rao, V.R., Evaluation of PARKIN gene variants in West Bengal Parkinson's disease patients. J. Hum. Genet. 55 (2015), 1–8.
40. Scaravilli, T., Gasparoli, E., Rinaldi, F., Polesello, G., Bracco, F., Health-related quality of life and sleep disorders in Parkinson's disease. Neurol. Sci. 24 (2003), 209–210.
41. Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., Trockenbacher, A., Schneider, R., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001), 263–269.
42. Shulman, J.M., De Jager, P.L., Feany, M.B., Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol.: Mech. Dis. 6 (2011), 193–222.
43. Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25 (2010), 603–605.
44. Wang, M., Hattori, N., Matsumine, H., Kobayashi, T., Yoshino, H., Morioka, A., et al. Polymorphism in the parkin gene in sporadic Parkinson's disease. Ann. Neurol. 45 (1999), 655–658.
45. Wu, Y.R., Wu, C.H., Chao, C.Y., Kuan, C.C., Zhang, W.L., Wang, C.K., et al. Genetic analysis of Parkin in early onset Parkinson's disease (PD): Novel intron 9 g > a single nucleotide polymorphism and risk of Taiwanese PD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153 (2010), 229–234.
46. Ye, S., Dhillon, S., Ke, X., Collins, A.R., Day, An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res., 29, 2001, e88.
47. Ziegler, A., Van Steen, K., Wellek, S., Investigating Hardy-Weinberg equilibrium in case-control or cohort studies or meta-analysis. Breast Cancer Res. Treat. 128 (2011), 197–201.